Cargando…
Maximal androgen blockade for advanced prostate cancer
Prostate cancer has now become one of the leading types of cancer in urban India. It is now the third most common cancer in Delhi. As we advance in health care with the resultant increase in longevity, we will be seeing more of advanced carcinoma prostate. Since the early 1980.s, there have been man...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878429/ https://www.ncbi.nlm.nih.gov/pubmed/20535304 http://dx.doi.org/10.4103/0970-1591.60463 |
_version_ | 1782181867651334144 |
---|---|
author | Mukha, Rajiv Paul Kumar, Santosh Kekre, N. S. |
author_facet | Mukha, Rajiv Paul Kumar, Santosh Kekre, N. S. |
author_sort | Mukha, Rajiv Paul |
collection | PubMed |
description | Prostate cancer has now become one of the leading types of cancer in urban India. It is now the third most common cancer in Delhi. As we advance in health care with the resultant increase in longevity, we will be seeing more of advanced carcinoma prostate. Since the early 1980.s, there have been many trials on MAB. However, the question remains whether these agents actually make a difference? The role of MAB is probably limited to the prevention of the β are reaction in patients on LHRH agonists. The non steroidal antiandrogens have a marginal benefit of increased overall survival by approximately 3% to 5% at 5 ve years. There may be a role for MAB in patients with metastatic carcinoma of prostate, low volume metastases, patients with M 1 disease with absence of metastases in the skull, ribs, long bones, and soft tissues excluding lymph nodes. |
format | Text |
id | pubmed-2878429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Medknow Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-28784292010-06-09 Maximal androgen blockade for advanced prostate cancer Mukha, Rajiv Paul Kumar, Santosh Kekre, N. S. Indian J Urol Evidence Based Urology Prostate cancer has now become one of the leading types of cancer in urban India. It is now the third most common cancer in Delhi. As we advance in health care with the resultant increase in longevity, we will be seeing more of advanced carcinoma prostate. Since the early 1980.s, there have been many trials on MAB. However, the question remains whether these agents actually make a difference? The role of MAB is probably limited to the prevention of the β are reaction in patients on LHRH agonists. The non steroidal antiandrogens have a marginal benefit of increased overall survival by approximately 3% to 5% at 5 ve years. There may be a role for MAB in patients with metastatic carcinoma of prostate, low volume metastases, patients with M 1 disease with absence of metastases in the skull, ribs, long bones, and soft tissues excluding lymph nodes. Medknow Publications 2010 /pmc/articles/PMC2878429/ /pubmed/20535304 http://dx.doi.org/10.4103/0970-1591.60463 Text en © Indian Journal of Urology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Evidence Based Urology Mukha, Rajiv Paul Kumar, Santosh Kekre, N. S. Maximal androgen blockade for advanced prostate cancer |
title | Maximal androgen blockade for advanced prostate cancer |
title_full | Maximal androgen blockade for advanced prostate cancer |
title_fullStr | Maximal androgen blockade for advanced prostate cancer |
title_full_unstemmed | Maximal androgen blockade for advanced prostate cancer |
title_short | Maximal androgen blockade for advanced prostate cancer |
title_sort | maximal androgen blockade for advanced prostate cancer |
topic | Evidence Based Urology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878429/ https://www.ncbi.nlm.nih.gov/pubmed/20535304 http://dx.doi.org/10.4103/0970-1591.60463 |
work_keys_str_mv | AT mukharajivpaul maximalandrogenblockadeforadvancedprostatecancer AT kumarsantosh maximalandrogenblockadeforadvancedprostatecancer AT kekrens maximalandrogenblockadeforadvancedprostatecancer |